Morphological aspects of type II alveolar pneumocytes following treatment with puromycin in vivo.
Ultrastructural modifications of type II pneumocytes (PNM-II) in mice were analysed 125 and 155 minutes after puromycin treatment (12 mg/100 gm at 0, 30, 60 and 90 minutes). A quantitative evaluation of the cell compartments was carried out and the inhibition of protein synthesis in PNM-II was monitored by light microscopic radioautography, following 3H-leucine injection. In electron micrographs, following a 125-minute puromycin treatment, the number and size of lamellar bodies, the precursors of lung surfactant material appeared markedly reduced. The multivesicular bodies (MVB), which are normally very frequent in PNM-II, had almost completely disappeared, as had composite bodies. Golgi saccules were dilated, while the area occupied by Golgi vesicles was enlarged. Observations following the 155-minute puromycin treatment showed a strong enhancement of these modifications. Smooth and coated vesicles of the Golgi area, as well as peroxisomes, did not appear modified by puromycin. Elongated zones of autophagy were more prevalent after 125-minute treatment than after the 155-minute one. Small bodies were frequently observed in the cytoplasm, near the Golgi zone. They were bounded by a smooth membrane and contained tiny vesicles and/or electron-dense lamellae similar to those present within the lamellar bodies. Parallel membranes formed folds, some of them in continuity with lamellar bodies, thus encircling portions of cytoplasm. These structures, which were few in number in controls, were very frequently observed in treated cells, mainly after the 125-minute treatment. These extensive alterations of PNM-II morphology appeared to be related to a disturbed production of pulmonary surfactant.
D000818:Animals; D003593:Cytoplasm / Q000187:drug effects; D004721:Endoplasmic Reticulum / Q000187:drug effects; D006056:Golgi Apparatus / Q000187:drug effects; D008297:Male; D051379:Mice; D008854:Microscopy, Electron; D010587:Phagocytosis / Q000187:drug effects; D014176:Protein Biosynthesis; D011650:Pulmonary Alveoli / Q000166:cytology / Q000187:drug effects*; D011663:Pulmonary Surfactants / Q000096:biosynthesis; D011691:Puromycin / Q000494:pharmacology*; D013997:Time Factors
D011663:Pulmonary Surfactants; D011691:Puromycin